Prasugrel

Prasugrel, sold as Effient, is an antiplatelet medicine of the P2Y12 inhibitor class. The US label read lists one use: lowering the rate of thrombotic cardiovascular events, including stent thrombosis, in people with acute coronary syndrome who are to be managed with percutaneous coronary intervention (PCI (percutaneous coronary intervention)). That covers unstable angina or non-ST-elevation heart attack, and ST-elevation heart attack managed with primary or delayed PCI. The label carries a boxed warning that the medicine can cause significant, sometimes fatal, bleeding.

Also called Effient

  • Drug
  • In this atlas

Overview

Technical summary

RxNorm ingredient 613391. MeSH descriptor D000068799 is Prasugrel Hydrochloride, the salt, so it is a broad match; MeSH has no descriptor for prasugrel itself. UNII G89JQ59I13 is the UNII of prasugrel hydrochloride, the salt the label names, and is a broad match. The label read is the Cosette Pharmaceuticals, Inc. label for Effient, application NDA022307, effective 2022-09-07 in openFDA; a newer label may exist outside openFDA. Generic prasugrel labels were not read. This page records label indications, the first line of the boxed warning and the class only: no trial result and no dose is given.

Trials at a glance

The figures count the 27 registry trials in this atlas that name this drug or a product that contains it. Trials that use another name for it are not counted.

Trials
27
Phase 3 or 4
25
Recruiting
2
Regulatory decisions
0
Trials by phase (rows) and registry status (columns)
PhaseRecruitingCompletedTerminatedUnknown statusAll statuses
Phase 201001
Phase 2/301001
Phase 314016
Phase 41142219
All phases2202327

Conditions these trials study

Sponsors with the most trials

The lead sponsor of each trial, as the registry names it.

And 20 more.

About this drug

Level
Substance
Mechanism
The label says an active metabolite of prasugrel binds irreversibly to the P2Y12 class of ADP receptors on platelets, which inhibits platelet activation and aggregation.

Classification codes

  • UNII G89JQ59I13
  • MeSH read 2026-11-09 D000068799

Claims and evidence

Context People for whom the US label of prasugrel (Effient) lists an indication: acute coronary syndrome managed with percutaneous coronary intervention

Recipient
Recipient not specified
Population
Patients described in the indications section of the label. The label passages read do not state an age range.
Care setting
Prescription medicine, as described in the US label
Geography
United States (label of the US Food and Drug Administration)
Life stage
Not stated in the label passages read
Gestational age
Not reported
Postnatal age
Not reported
Follow-up
Not applicable (label statement)
Eligibility: 2 inclusion criteria; exclusion criteria not stated
Included
Excluded
None stated
  • Description Evidence stage not applicable Certainty not assessed

    The US label of Effient (prasugrel), in the Cosette Pharmaceuticals, Inc. version dated 2022-09-07 in openFDA, lists the medicine to reduce the rate of thrombotic cardiovascular events, including stent thrombosis, in patients with acute coronary syndrome who are to be managed with percutaneous coronary intervention (PCI): patients with unstable angina or non-ST-elevation myocardial infarction, and patients with ST-elevation myocardial infarction managed with primary or delayed PCI. The label carries a boxed warning that the medicine can cause significant, sometimes fatal, bleeding.

    Applies to Recipient not specified People for whom the US label of prasugrel (Effient) lists an indication: acute coronary syndrome managed with percutaneous coronary intervention

    Certainty method
    Not assessed
    Limitations
    This claim records what the label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. Only the indications, the first line of the boxed warning and the mechanism sentence were read; the rest of the boxed warning, contraindications, doses, interactions and other warnings were not recorded. Labels change, and openFDA's version may be older than the current label. openFDA's own disclaimer says not to rely on it for decisions about medical care.
    Last checked
    2026-11-09
    Next evidence check due
    Not scheduled
    Sources and citations (6)
    1. Supports openFDA drug label record for EFFIENT (prasugrel tablets), Cosette Pharmaceuticals, Inc. label: indications, mechanism and boxed warning

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id 69ea2d58-5353-4222-b61f-cab976fa7e5e (manufacturer Cosette Pharmaceuticals, Inc., application NDA022307), returned on 2026-11-09. The label text is dated 2022-09-07 (effective_time). No other openFDA record of an Effient label was returned by a brand-name search. Generic prasugrel labels were not read.

      Locator
      results[0].indications_and_usage[0], 1 INDICATIONS AND USAGE
      How it applies
      Label passage quoted in the research quote table (LB-04).
      Retrieved
      Source effective date
      2022-09-07
      Source state
      Current
      Version fingerprint
      f8a4f19a1b4b960d4c2bea9f3fa9e117b0f10c7b0375ddaad4c490f294932a94
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
    2. Supports openFDA drug label record for EFFIENT (prasugrel tablets), Cosette Pharmaceuticals, Inc. label: indications, mechanism and boxed warning

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id 69ea2d58-5353-4222-b61f-cab976fa7e5e (manufacturer Cosette Pharmaceuticals, Inc., application NDA022307), returned on 2026-11-09. The label text is dated 2022-09-07 (effective_time). No other openFDA record of an Effient label was returned by a brand-name search. Generic prasugrel labels were not read.

      Locator
      results[0].indications_and_usage[0], 1.1 Acute Coronary Syndrome
      How it applies
      Label passage quoted in the research quote table (LB-05).
      Retrieved
      Source effective date
      2022-09-07
      Source state
      Current
      Version fingerprint
      f8a4f19a1b4b960d4c2bea9f3fa9e117b0f10c7b0375ddaad4c490f294932a94
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
    3. Supports openFDA drug label record for EFFIENT (prasugrel tablets), Cosette Pharmaceuticals, Inc. label: indications, mechanism and boxed warning

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id 69ea2d58-5353-4222-b61f-cab976fa7e5e (manufacturer Cosette Pharmaceuticals, Inc., application NDA022307), returned on 2026-11-09. The label text is dated 2022-09-07 (effective_time). No other openFDA record of an Effient label was returned by a brand-name search. Generic prasugrel labels were not read.

      Locator
      results[0].indications_and_usage[0], 1.1 Acute Coronary Syndrome, unstable angina or NSTEMI
      How it applies
      Label passage quoted in the research quote table (LB-06).
      Retrieved
      Source effective date
      2022-09-07
      Source state
      Current
      Version fingerprint
      f8a4f19a1b4b960d4c2bea9f3fa9e117b0f10c7b0375ddaad4c490f294932a94
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
    4. Supports openFDA drug label record for EFFIENT (prasugrel tablets), Cosette Pharmaceuticals, Inc. label: indications, mechanism and boxed warning

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id 69ea2d58-5353-4222-b61f-cab976fa7e5e (manufacturer Cosette Pharmaceuticals, Inc., application NDA022307), returned on 2026-11-09. The label text is dated 2022-09-07 (effective_time). No other openFDA record of an Effient label was returned by a brand-name search. Generic prasugrel labels were not read.

      Locator
      results[0].indications_and_usage[0], 1.1 Acute Coronary Syndrome, STEMI
      How it applies
      Label passage quoted in the research quote table (LB-07).
      Retrieved
      Source effective date
      2022-09-07
      Source state
      Current
      Version fingerprint
      f8a4f19a1b4b960d4c2bea9f3fa9e117b0f10c7b0375ddaad4c490f294932a94
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
    5. Supports openFDA drug label record for EFFIENT (prasugrel tablets), Cosette Pharmaceuticals, Inc. label: indications, mechanism and boxed warning

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id 69ea2d58-5353-4222-b61f-cab976fa7e5e (manufacturer Cosette Pharmaceuticals, Inc., application NDA022307), returned on 2026-11-09. The label text is dated 2022-09-07 (effective_time). No other openFDA record of an Effient label was returned by a brand-name search. Generic prasugrel labels were not read.

      Locator
      results[0].boxed_warning[0], sentence 1
      How it applies
      Label passage quoted in the research quote table (LB-08).
      Retrieved
      Source effective date
      2022-09-07
      Source state
      Current
      Version fingerprint
      f8a4f19a1b4b960d4c2bea9f3fa9e117b0f10c7b0375ddaad4c490f294932a94
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
    6. Background openFDA drug label record for EFFIENT (prasugrel tablets), Cosette Pharmaceuticals, Inc. label: indications, mechanism and boxed warning

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id 69ea2d58-5353-4222-b61f-cab976fa7e5e (manufacturer Cosette Pharmaceuticals, Inc., application NDA022307), returned on 2026-11-09. The label text is dated 2022-09-07 (effective_time). No other openFDA record of an Effient label was returned by a brand-name search. Generic prasugrel labels were not read.

      Locator
      results[0].effective_time
      How it applies
      Effective date of the label text read, 20220907.
      Retrieved
      Source effective date
      2022-09-07
      Source state
      Current
      Version fingerprint
      f8a4f19a1b4b960d4c2bea9f3fa9e117b0f10c7b0375ddaad4c490f294932a94
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.

FDA label

The FDA label of the application holder, as the openFDA label dataset holds it, for the products that contain this drug.

EFFIENT

No label from the application holder was found in the openFDA label dataset for application NDA022307. This page does not show another labeler's label in its place.

FDA decisions timeline

The regulatory decisions of the FDA that this atlas holds for this drug and the products that contain it, oldest first. Each links to its full record.

  1. Approval NDA022307 EFFIENT
  2. Supplemental approval NDA022307 EFFIENT
  3. Supplemental approval NDA022307 EFFIENT

Clinical links

Each link reports what one cited claim says about one population. "Evaluated for" means studied, not shown to work. These links do not show that anything is effective or right for you.

Registry records

Assembled by a program from ClinicalTrials.gov and openFDA. No person wrote or checked these pages, and they are counted apart from the pages that people wrote. Lists of trials come from the registry's own coding and may miss trials.

Registry products 1

  • A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and 2 efficacy supplement approvals on record.

    ProductNDA022307

Registry trials 27

Record details

Record id
cardio:prasugrel
Content hash
5950f34e37898707d193b68076622cc568f78e299a73cfb8e37f8b8013ecec24